Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial Yutao Guo,

Slides:

Advertisements

Similar presentations

Hypertension treatment guidelines from the United Kingdom’s National Institute for Health and Care Excellence. Guidelines identify angiotensin-converting.

Advertisements

Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema Harikrishna Makani, MD, Sripal Bangalore, MD, MHA,

New-onset Atrial Fibrillation Predicts Heart Failure Progression

Volume 112, Issue 3, Pages (September 1997)

Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer Russell D. Hull, MBBS, MSc, Graham F. Pineo,

Isolated Systolic Hypertension: An Update After SPRINT

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

An Unusual Cause of Leg Ulcerations

Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II Menno V. Huisman,

Characteristics of Hospitalized Patients with Atrial Fibrillation in Taiwan: A Nationwide Observation Cheng-Han Lee, MD, Ping-Yen Liu, MD, PhD, Liang-Miin.

Acute Paralysis in a Uremic Patient

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review Shelley R. Salpeter, MD, Jacob S.

Volume 137, Issue 2, Pages (February 2010)

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Comparative Effectiveness Research and Medical Informatics

Scientific and Organizational Collaboration in Comparative Effectiveness Research: The VA Cooperative Studies Program Model Grant D. Huang, MPH, PhD,

Innovative Informatics Approaches for Peripheral Artery Disease: Current State and Provider Survey of Strategies for Improving Guideline-Based Care Alisha.

Bertha Wong, MD, Muhammad M. Mamdani, PharmD, MPH, Catherine H

Jason Thomas, MD, Erica Saenz, MD, Paul Haggerty, MD

Leslie R. Harrold, MD, MPH, Daniel Peterson, MS, Ashley J

Sayed H. Naderi, BMedSci, Jonathan P. Bestwick, MSc, David S. Wald, MD

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks Sripal Bangalore, MD, MHA, Gbenga Ogedegbe,

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

‘Real-World’ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey Gregory Y.H. Lip, MD, Cécile Laroche, MSc, Gheorghe-Andrei Dan,

Thomas E. MacMillan, MD, MSc, Terence Tang, MD, Rodrigo B

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Franz H. Messerli, MD, Sripal Bangalore, MD, MHA

Prevention of Anaphylaxis: The Role of the Epinephrine Auto-Injector

Membranous nephropathy: When and how to treat

Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer Russell D. Hull, MBBS, MSc, Graham F. Pineo,

Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus George L. Bakris, MD Mayo Clinic.

All-cause Mortality Associated with TNF-α Inhibitors in Rheumatoid Arthritis: A Meta- Analysis of Randomized Controlled Trials Lucile Poiroux, MD, Yannick.

Serotonin Syndrome Masquerading as Ventricular Tachycardia Storm

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

The Reply The American Journal of Medicine

Preventing and Treating Acute Kidney Injury Among Hospitalized Patients with Cirrhosis and Ascites: A Narrative Review Elliot B. Tapper, MD, Alan Bonder,

Notifications Received by Primary Care Practitioners in Electronic Health Records: A Taxonomy and Time Analysis Daniel R. Murphy, MD, MBA, Brian Reis,

Characteristics of Contemporary Patients Discharged From the Hospital After an Acute Coronary Syndrome Robert J. Goldberg, PhD, Jane S. Saczynski, PhD,

History of Thyroid Disorders in Relation to Clinical Outcomes in Atrial Fibrillation Helene Bruere, MD, Laurent Fauchier, MD, PhD, Anne Bernard Brunet,

The New Lipid Guidelines: What Do Primary Care Clinicians Think?

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Volume 72, Issue 12, Pages (December 2007)

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

External Validation of the Simple NULL-PLEASE Clinical Score in Predicting Outcome of Out-of-Hospital Cardiac Arrest Tatjana S. Potpara, MD, PhD, Miroslav.

Does Methylphenidate Reduce the Symptoms of Chronic Fatigue Syndrome?

Jennifer Tjia, MD, MSCE, Jeroan Allison, MD, Jane S

Effect of Spironolactone on Physical Performance in Older People with Self-reported Physical Disability Louise A. Burton, MD, Deepa Sumukadas, MD, Miles.

Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema Harikrishna Makani, MD, Sripal Bangalore, MD, MHA,

Statin Use and Risk of COPD Exacerbation Requiring Hospitalization

Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey Maura Marcucci, MD, Gregory Y.H. Lip,

Ali Ahmed, MD, MPH, Michael W. Rich, MD, Michael Zile, MD, Paul W

Ali Ahmed, MD, Gregg C. Fonarow, MD, Yan Zhang, MS, MSPH, Paul W

The future of renoprotection: Frustration and promises

National Trends in Ambulatory Oral Anticoagulant Use

Isolated Systolic Hypertension: An Update After SPRINT

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Volume 73, Issue 5, Pages (March 2008)

Primary Care Management of Skin Abscesses Guided by Ultrasound

Trends in Prolonged Hospitalizations in the United States from 2001 to 2012: A Longitudinal Cohort Study Lauren Doctoroff, MD, Douglas J. Hsu, MD, Kenneth.

Rebecca D. Chason, Joan S. Reisch, PhD, Don C. Rockey, MD

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

Bijin Thajudeen, MD, Mario F. Rubin, MD

David Tian, MD, Ram Jhingan Mohan, MD, Gary Stallings, MD

Presentation transcript:

Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial Yutao Guo, MD, PhD, Yundai Chen, MD, PhD, Deirdre A. Lane, PhD, Lihong Liu, MD, Yutang Wang, MD, PhD, Gregory Y.H. Lip, MD The American Journal of Medicine Volume 130, Issue 12, Pages 1388-1396.e6 (December 2017) DOI: 10.1016/j.amjmed.2017.07.003 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Patients' knowledge of atrial fibrillation with usual care and mAF App at baseline, 1 month, and 3 months. *P for trend <.05 at baseline, 1 month, and 3 months after discharge. The American Journal of Medicine 2017 130, 1388-1396.e6DOI: (10.1016/j.amjmed.2017.07.003) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Time trends for quality of life scores of patients with the mAF App. *Quality of life questionnaire was cited from the EuroQol. Compared with patients with usual care, patients with the mAF App, P < .05. The American Journal of Medicine 2017 130, 1388-1396.e6DOI: (10.1016/j.amjmed.2017.07.003) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Antithrombotic treatment in patients with the mAF App and usual care at baseline, 1 month, and 3 months after discharge. A, Usual care. B, mAF App. The American Journal of Medicine 2017 130, 1388-1396.e6DOI: (10.1016/j.amjmed.2017.07.003) Copyright © 2017 The Authors Terms and Conditions

Supplementary Figure 1 Flow chart. The American Journal of Medicine 2017 130, 1388-1396.e6DOI: (10.1016/j.amjmed.2017.07.003) Copyright © 2017 The Authors Terms and Conditions

Supplementary Figure 2 Clinical decision support. The American Journal of Medicine 2017 130, 1388-1396.e6DOI: (10.1016/j.amjmed.2017.07.003) Copyright © 2017 The Authors Terms and Conditions

Supplementary Figure 3 Patients' educational program. *Patients followed the educational program on their mobile device to improve their knowledge of atrial fibrillation and learn how to manage themselves at home. The American Journal of Medicine 2017 130, 1388-1396.e6DOI: (10.1016/j.amjmed.2017.07.003) Copyright © 2017 The Authors Terms and Conditions

Supplementary Figure 4 Patients' involvement in self-care. *Patients could monitor their blood pressure and pulse rate, and be involved in their management. The American Journal of Medicine 2017 130, 1388-1396.e6DOI: (10.1016/j.amjmed.2017.07.003) Copyright © 2017 The Authors Terms and Conditions

Supplementary Figure 5 Structured follow-up in patients with the mAF App. *The structured follow-up was planned at 1, 3, 6, 9, and 12 months after consultation/discharge, and included drug therapy, thrombotic events, bleeding events, quality of life, anticoagulant satisfaction, and mAF App investigation. A reminder alert was sent automatically to patients 1 week before and after the follow-up time-point by the mAF App. The American Journal of Medicine 2017 130, 1388-1396.e6DOI: (10.1016/j.amjmed.2017.07.003) Copyright © 2017 The Authors Terms and Conditions

Supplementary Figure 6 Usability, feasibility, and acceptability of the mAF App at 1 month. *A total of 110 patients with the mAF App fulfilled the investigation. The American Journal of Medicine 2017 130, 1388-1396.e6DOI: (10.1016/j.amjmed.2017.07.003) Copyright © 2017 The Authors Terms and Conditions

Supplementary Figure 7 Drugs in patients with the mAF App and usual care at baseline, 1 month, and 3 months. A, Usual care. B, mAF App. ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor inhibitor; CCB = calcium channel blocker. Antiarrhythmic drugs: propafenone and amiodarone. Glucose-lowering drugs: insulin, acarbose, glimepiride, and metformin. Other lipid-lowering drugs: ezetimibe and probucol. The American Journal of Medicine 2017 130, 1388-1396.e6DOI: (10.1016/j.amjmed.2017.07.003) Copyright © 2017 The Authors Terms and Conditions